在山羊中静脉注射不同剂量的卡普罗芬的药理动力学
Orhan Corum1, Halis Oguz2, Mustafa Hitit3
1Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Hatay Mustafa Kemal, Hatay 31060, Türkiye.
Veterinary sciences
|September 27, 2025
概括
这项研究评估了山羊的卡普罗的药理动力学. 较高剂量可能会延长药物的效果,但在一次性使用后可能在临床上无意义,因此在重复治疗时需要谨慎.
科学领域:
- 兽医药理学 兽医药理学
- 动物药物代谢动物药物代谢
背景情况:
- 卡普罗芬是一种常用于兽医的非类固醇抗炎药物 (NSAID).
- 了解其在山羊中的药理动力学特征对于安全有效的治疗用途至关重要.
研究的目的:
- 为了确定子静脉注射卡普罗芬的药理学参数.
- 为了评估不同剂量水平 (0.7,1.4和4毫克/公斤) 对卡普罗芬的排放的影响.
主要方法:
- 18只山羊被分为三组 (每组n=6),并以不同剂量的静脉注射卡尔芬.
- 血样本是在给药后的22个时间点收集的.
- 使用紫外线检测 (HPLC-UV) 的高性能液体色谱和非分区分析来确定药理动力学参数.
主要成果:
- 在0.7 mg/kg的剂量下,卡普罗芬的总清除值 (CLT) 为2.19 mL/h/kg,稳定状态分布量 (Vdss) 为126.56 mL/kg,排泄半衰期 (t1/2λz) 为44.32 h.
- 在较高剂量 (1.4和4毫克/公斤) 时,观察到清除和分布量的增加.
- 建议剂量取决于药物效应持续时间的增加,尽管单次服用后的差异可能在临床上无关紧要.
结论:
- 卡普罗芬适用于研究剂量范围 (0.7至4毫克/公斤) 的山羊的静脉注射.
- 在较高剂量下,长时间药物效应的可能性值得考虑,特别是在重复剂量方案中.
- 建议对副作用和药物残留进行仔细监测,特别是在山羊重复接受卡尔治疗时.
相关概念视频
Dosage Regimens: Partial Pharmacokinetic Parameters
154
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
154
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
233
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
233
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
253
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
253
Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection
407
In pharmacokinetics, the elimination rate of a drug following a capacity-limited model is primarily controlled by two parameters: Vmax and KM. These parameters are crucial in how the drug behaves inside the body after administration.
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
407
Nonlinear Pharmacokinetics: Overview
1.1K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
214
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
214


